Aethlon Medical Files 10-K/A Amendment

TL;DR

AETH filed an amendment to its 2024 10-K, check for updates.

AI Summary

Aethlon Medical, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. This amendment, filed on August 15, 2024, provides updated information for the period. The company is incorporated in Nevada and its principal executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California.

Why It Matters

This filing indicates Aethlon Medical is providing updated or corrected information for its annual report, which is crucial for investors to have the most accurate financial and operational data.

Risk Assessment

Risk Level: medium — Amendments to SEC filings can sometimes indicate significant changes or corrections to previously reported information, warranting closer investor scrutiny.

Key Numbers

• 001-37487 — SEC File Number (Identifies the company's filings with the SEC)
• 13-3632859 — IRS Number (Company's Employer Identification Number)

Key Players & Entities

• Aethlon Medical, Inc. (company) — Registrant
• 0001683168-24-005774 (filing_id) — Accession Number
• 20240815 (date) — Filing Date
• March 31, 2024 (date) — Fiscal Year End
• 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — T: TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAME
• $5.5 m — leted second quarter) was approximately $5.5 million, computed by reference to the clo
• $2.258 — osing sale price of the common stock of $2.258 per share on the Nasdaq Capital Market

Filing Documents

• aethlon_i10ka1-033124.htm (10-K/A) — 273KB
• aethlon_ex3101.htm (EX-31.1) — 3KB
• 0001683168-24-005774.txt ( ) — 278KB

Executive Compensation

Executive Compensation 6 Item 12.

Security Ownership of Certain Beneficial

Security Ownership of Certain Beneficial 11 Item 13. Certain Relationships and Related Transactions, and Director Independence 13 Item 14. Principal Accountant Fees and Services 15 PART IV . Item 15. Exhibits and Financial Statement Schedules 16

Signatures

Signatures 20 i PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE The names, ages and positions of our directors and executive officers as of July 29, 2024 are listed below: NAMES TITLE OR POSITION (1) AGE James B. Frakes Interim Chief Executive Officer, Chief Financial Officer and Director 67 Edward G. Broenniman Chairman and Director 88 Angela Rossetti Director 71 Chetan S. Shah, M.D. Director 55 Nicolas Gikakis Director 58 Guy F. Cipriani Senior Vice President, Chief Operating Officer 54 Steven P. LaRosa, M.D. Chief Medical Officer 57 (1) Our Board of Directors has determined that Mr. Broenniman, Mr. Gikakis, Ms. Rossetti and Dr. Shah meet the requirements to be determined as "independent directors" for all purposes, including Compensation Committee and Audit Committee purposes, under the Nasdaq Stock Market ("Nasdaq") rules and for federal securities law purposes. Mr. Frakes is not independent, as he also functions as executive and officer of the Company. Certain additional information concerning the individuals named above is set forth below. This information is based on information furnished to us by each individual noted. James B. Frakes, Interim Chief Executive Officer, Chief Financial Officer and Director Mr. Frakes has served as Interim Chief Executive Officer and as a director of the Company since November 2023, and has served as Chief Financial Officer of the Company since September 2010. Prior to being appointed as Chief Financial Officer, Mr. Frakes served as Senior Vice President, Finance of the Company from January 2008 to September 2010. He previously served as the Chief Financial Officer for Left Behind Games Inc., a start-up video game company. Prior to 2006, he served as Chief Financial Officer of NTN Buzztime, Inc., an interactive entertainment company. Mr. Frakes received an MBA from the University of Southern California and a B.A. with Honors from Stanford University. Edward G. Broenniman,

Legal Proceedings

Legal Proceedings To our knowledge, (i) no director or executive officer has been a director or executive officer of any business that has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years; (ii) no director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the past ten years; (iii) no director or executive officer has been the subject of any order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities during the past ten years; and (iv) no director or officer has been found by a court to have violated a federal or state securities or commodities law during the past ten years. Board of Directors Our Board of Directors has the responsibility for establishing broad corporate policies and for overseeing our overall performance. Members of our Board of Directors are kept informed of our business activities through discussions with our Interim Chief Executive Officer and other executive officers, by reviewing analyses and reports sent to them and by participating in Board and committee meetings. Mr. Broenniman serves as Chairman of our Board and Mr. Frakes as our Interim Chief Executive Officer, and we have not designated a lead independent director. We believe that having the offices of Chairman of our Board and Interim Chief Executive Officer held by two different people is appropriate for a company of our size and stage of development in order to maximize efficiencies of our limited available personnel resources. Nevada law provides that each director holds office after the expiration of his or her term until a successor is elected and qualified, or until the director resigns or is removed, resulting in a term that extends to our next annual meeting of stockholders. Our Board of Directors presently has an Audit Commi

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION We are a "smaller reporting company" under Item 10 of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the following compensation disclosure is intended to comply with the requirements applicable to smaller reporting companies. Although the rules allow us to provide less detail about our executive compensation program, the Compensation Committee of our Board of Directors (the "Compensation Committee") is committed to providing the information necessary to help stockholders understand its executive compensation-related decisions. Accordingly, this section includes supplemental narratives that describe the 2024 fiscal year executive compensation program for our named executive officers. Our named executive officers (our interim and former principal executive officers and our two most highly com

View Full Filing

View this 10-K/A filing on SEC EDGAR